Volume 29, Issue 162, August 2025

Lazertinib and amivantamab in the treatment of lung cancer with EGFR mutation

Agata Żak-Gontarz^1♦, Barbara Anna Zapalska², Antonina Teresa Witkowska³, Aleksandra Minda⁴, Justyna Janikowska⁵, Julia Piotrowska⁶, Aleksandra Łubińska- Kowalska⁶, Adrianna Domańska⁶, Adrianna Witkowska⁶, Monika Wendland⁷, Krzysztof Julian Długosz⁸

¹Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, Poland
²Independent Public Central Clinical Hospital of University Clinical Centre of Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland
³Praga Hospital of the Transfiguration of the Lord, Aleja Solidarności 67, 03- 401 Warsaw, Poland
⁴The Infant Jesus Clinical Hospital, Williama Heerleina Lindleya 4, 02-005, Warsaw, Poland
⁵National Medical Institute of the Ministry of the Interior and Administration in Warsaw, Wołoska 137, 02-507 Warsaw, Poland
⁶University of Warmia and Mazury, Aleja Warszawska 30, 11-082 Olsztyn, Poland
⁷Mazovian “Bródnowski” Hospital, Ludwika Kondratowicza 8, 03-242 Warsaw, Poland
⁸Clinical University Hospital in Olsztyn, Aleja Warszawska 30, 11-041 Olsztyn, Poland

^♦Corresponding author
Agata Żak-Gontarz, Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, Poland

ABSTRACT

Worldwide, the leading cause of mortality is lung cancer. There are two most common types of this cancer: non-small cell lung cancer (NSCLC), which is in first place in prevalence, and small cell lung cancer (SCLC). Lack of health screening and nonspecific symptoms are the leading causes of diagnosis in advanced or metastatic states. Late detection and resistance to therapy are the reasons why the prognosis remains poor. Lifestyle, environmental factors, and genetic mutations contribute to the development of lung cancer. The most common proto-oncogene in non-small cell lung cancer is EGFR. Upon mutation, it becomes an oncogene, which is a potential therapeutic target. This study aims to review the innovative guidelines for locally advanced or metastatic NSCLC with EGFR mutations. One of the wellknown third-generation EGFR tyrosine kinase inhibitors (TKIs) is Osimertinib. Unfortunately, it quickly developed resistance. There is a significant need to overcome resistance by combining lazertinib with amivantamab in both first- and second-line treatments. These drugs work through a different mechanism, allowing them to attack cancer cells from multiple angles. Studies like Mariposa, Mariposa-2, Papillon, Chrysalis, and Chrysalis-2 show new therapeutic options for patients with Locally Advanced or Metastatic NSCLC with EGFR Mutation (Ex20ins, ex19del, p.L858R). Furthermore, some studies show that reducing amivantamab's side effects and improving patient comfort can be achieved. There are two opinions: one is additional dexamethasone premedication, and the second is switching its administration from intravenous to subcutaneous.

Keywords: lazertinib, amivantamab, lung cancer

Medical Science, 2025, 29, e135ms3677

PDF

DOI: https://doi.org/10.54905/disssi.v29i162.e135ms3677

Published: 18 August 2025